Prevention and therapy of threatened preterm birth in multiple pregnancy

Cover Page


Cite item

Full Text

Abstract

Preterm birth in multiple pregnancy is an important medical, economic and social problem. Currently, more than half of twins are born prematurely, which puts them at high risk of developing neonatal diseases causing lifelong disability and social maladjustment. In this regard, reducing the frequency of preterm multiple births is an important task of modern obstetrics. Improving perinatal outcomes of multiple pregnancies can only be achieved using the most effective measures that have a good evidence base. At the same time, numerous studies on the effectiveness of therapeutic interventions aimed at prolonging multiple pregnancies have reported contradictory results. This review included most of the randomized controlled trials of methods for the prevention and treatment of threatening preterm birth in multiple pregnancies, as available in PubMed, Google Academy, Elibrary, and the Cochrane Central Register of Controlled Trials. Thus far, studies on the use of bed rest, prophylactic tocolysis, most of the progestins, and cervical cerclage in multiple pregnancy have shown no efficacy in reducing the risk of premature birth. However, encouraging data were obtained on improving neonatal outcomes of multiple pregnancies using vaginal progesterone and an obstetric pessary, but these results require additional confirmation in larger multicenter randomized studies. Further clinical trials are needed to develop algorithms for timely diagnosis and adequate treatment of threatened preterm birth in case of multiple pregnancy, including the use of the most rational preventive and therapeutic methods that have a high evidence level.

About the authors

Olga V. Kosyakova

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Author for correspondence.
Email: for.olga.kosyakova@gmail.com
ORCID iD: 0000-0003-4116-0222
SPIN-code: 1204-3160

MD, Post-Graduate Student

Russian Federation, Saint Petersburg

Olesya N. Bespalova

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: shiggerra@mail.ru

MD, PhD, DSci (Medicine), Deputy Director for Research

Russian Federation, Saint Petersburg

References

  1. Bigelow C, Stone J. Bed rest in pregnancy. Mt Sinai J Med. 2011;78(2):291-302. https://doi.org/10.1002/msj.20243.
  2. Crowther CA, Han S. Hospitalisation and bed rest for multiple pregnancy. Cochrane Database Syst Rev. 2010(7):CD000110. https://doi.org/10.1002/14651858.CD000110.pub2.
  3. da Silva Lopes K, Takemoto Y, Ota E, et al. Bed rest with and without hospitalisation in multiple pregnancy for improving perinatal outcomes. Cochrane Database Syst Rev. 2017;3:CD012031. https://doi.org/10.1002/14651858.CD012031.pub2.
  4. Rafael TJ, Berghella V, Alfirevic Z. Cervical stitch (cerclage) for preventing preterm birth in multiple pregnancy. Cochrane Database Syst Rev. 2014(9):CD009166. https://doi.org/10.1002/14651858.CD009166.pub2.
  5. Saccone G, Rust O, Althuisius S, et al. Cerclage for short cervix in twin pregnancies: systematic review and meta-analysis of randomized trials using individual patient-level data. Acta Obstet Gynecol Scand. 2015;94(4):352-358. https://doi.org/10.1111/aogs.12600.
  6. Письмо Минздрава России от 17 декабря 2013 г. № 15-4/10/2-9480. Преждевременные роды. Клинические рекомендации (протокол лечения). [Letter of the Ministry of Health of Russia of 2013 Dec 17. Prezhdevremennye rody. Klinicheskie rekomendatsii (protokol lecheniya). (In Russ.)]
  7. Diamant H, Mastrolia SA, Weintraub AY, et al. Effectiveness and safety of late midtrimester cervical cerclage. J Matern Fetal Neonatal Med. 2019;32(18):3007-3011. https://doi.org/10.1080/14767058.2018.1454426.
  8. Roman A, Rochelson B, Fox NS, et al. Efficacy of ultrasound-indicated cerclage in twin pregnancies. Am J Obstet Gynecol. 2015;212(6):788.e781-786. https://doi.org/10.1016/j.ajog.2015.01.031.
  9. Khodzhaeva Z, Sukhikh G. Experience with cervical cerclage in multiple pregnancies. J Matern Fetal Neonatal Med. 2008;21.
  10. Беспалова О.Н., Саргсян Г.С. Акушерские пессарии в клинической практике // Журнал акушерства и женских болезней. – 2015. – Т. 64. – № 2. – C. 97–107. [Bespalova ON, Sargsyan GS. Pessaries in clinical practice. Journal of Obstetrics and Womenʼs Diseases. 2015;64(2):97-107. (In Russ.)]. https://doi.org/10.17816/JOWD64297-107.
  11. Козлов П.В. Истмико-цервикальная недостаточность: методические рекомендации / Под ред. Ю.Э. Доброхотова. – М., 2018. – 15 с. [Kozlov PV. Istmiko-tservikal’naya nedostatochnost’: metodicheskie rekomendatsii. Ed. by Y.E. Dobrokhotov. Moscow; 2018. (In Russ.)]
  12. Arabin B, Halbesma JR, Vork F, et al. Is treatment with vaginal pessaries an option in patients with a sonographically detected short cervix? J Perinat Med. 2003;31(2):122-133. https://doi.org/10.1515/JPM.2003.017.
  13. Liem S, Schuit E, Hegeman M, et al. Cervical pessaries for prevention of preterm birth in women with a multiple pregnancy (ProTWIN): a multicentre, open-label randomised controlled trial. Lancet. 2013;382(9901):1341-1349. https://doi.org/10.1016/s0140-6736(13)61408-7.
  14. Liem SM, van Baaren GJ, Delemarre FM, et al. Economic analysis of use of pessary to prevent preterm birth in women with multiple pregnancy (ProTWIN trial). Ultrasound Obstet Gynecol. 2014;44(3):338-345. https://doi.org/10.1002/uog.13432.
  15. Goya M, de la Calle M, Pratcorona L, et al. Cervical pessary to prevent preterm birth in women with twin gestation and sonographic short cervix: a multicenter randomized controlled trial (PECEP-Twins). Am J Obstet Gynecol. 2016;214(2):145-152. https://doi.org/10.1016/j.ajog.2015.11.012.
  16. van ‘t Hooft J, van der Lee JH, Opmeer BC, et al. Pessary for prevention of preterm birth in twin pregnancy with short cervix: 3-year follow-up study. Ultrasound Obstet Gynecol. 2018;51(5):621-628. https://doi.org/10.1002/uog.19029.
  17. Nicolaides KH, Syngelaki A, Poon LC, et al. Cervical pessary placement for prevention of preterm birth in unselected twin pregnancies: a randomized controlled trial. Am J Obstet Gynecol. 2016;214(1):3.e1-9. https://doi.org/10.1016/j.ajog.2015.08.051.
  18. Saccone G, Ciardulli A, Xodo S, et al. Cervical pessary for preventing preterm birth in twin pregnancies with short cervical length: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2017;30(24):2918-2925. https://doi.org/10.1080/14767058.2016.1268595.
  19. Berghella V, Dugoff L, Ludmir J. Prevention of preterm birth with pessary in twins (PoPPT): a randomized controlled trial. Ultrasound Obstet Gynecol. 2017;49(5):567-572. https://doi.org/10.1002/uog.17430.
  20. Bespalova O, Sargsyan G. The effectiveness of arabin pessary in twin pregnancy. Twin Res Hum Genet. 2017;20(S6).
  21. Патент РФ на изобретение № 156505/29.04.15. Бюл. № 3. Айламазян Э.К., Болотских В.М. Акушерский сакрализующий пессарий. [Patent RUS No. 156505/29.04.15. Byul. No. 3. Aylamazyan EK, Bolotskikh VM. Akusherskiy sakralizuyushchiy pessariy. (In Russ.)]
  22. Шнейдерман М.Г., Горшков А.В. Новые модели гинекологических и акушерских пессариев // Гинекология. – 2016. – T. 18. – № 2. – C. 92–95. [Shneyderman MG, Gorshkov AV. A new model of gynecological and obstetrical pessary. Ginekologiya. 2016;18(2):92-95. (In Russ.)]
  23. Зыгмунт М., Сапа Я. Прогестерон — новый взгляд на давно известное лекарство // Репродуктивна Ендокринологія. – 2017. – № 1. – C. 17–25. [Zygmunt M, Sapa Y. Progesteron — novyy vzglyad na davno izvestnoe lekarstvo. Reproduktivna Endokrinologіya. 2017;(1):17-25. (In Russ.)]
  24. Ших Е.В. Клинико-фармакологические аспекты применения дидрогестерона для сохранения беременности // Акушерство, гинекология и репродукция. – 2010. – Т. 4. – № 2. – C. 6–9. [Shikh EV. Clinical-pharmacological apects of the use of dydrogesterone in pregnancy maintenance. Akusherstvo, ginekologiya i reproduktsiya. 2010;4(2):6-9. (In Russ.)]
  25. Dodd JM, Grivell RM, CM OB, et al. Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy. Cochrane Database Syst Rev. 2017;10:CD012024. https://doi.org/10.1002/14651858.CD012024.pub2.
  26. El-Refaie W, Abdelhafez MS, Badawy A. Vaginal progesterone for prevention of preterm labor in asymptomatic twin pregnancies with sonographic short cervix: a randomized clinical trial of efficacy and safety. Arch Gynecol Obstet. 2016;293(1):61-67. https://doi.org/10.1007/s00404-015-3767-1.
  27. McNamara HC, Wood R, Chalmers J, et al. STOPPIT Baby Follow-up Study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. PLoS One. 2015;10(4):e0122341. https://doi.org/10.1371/journal.pone.0122341.
  28. Romero R, Conde-Agudelo A, El-Refaie W, et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. Ultrasound Obstet Gynecol. 2017;49(3):303-314. https://doi.org/10.1002/uog.17397.
  29. Agra IKR, Carvalho MHB, Hernandez WR, et al. The effect of prenatal vaginal progesterone on cervical length in nonselected twin pregnancies. J Matern Fetal Neonatal Med. 2019;32(8):1245-1249. https://doi.org/10.1080/14767058.2017.1403577.
  30. Awwad J, Usta IM, Ghazeeri G, et al. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity. BJOG. 2015;122(1):71-79. https://doi.org/10.1111/1471-0528.13031.
  31. Lim AC, Schuit E, Bloemenkamp K, et al. 17alpha-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial. Obstet Gynecol. 2011;118(3):513-520. https://doi.org/10.1097/AOG.0b013e31822ad6aa.
  32. Schuit E, Stock S, Rode L, et al. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis. BJOG. 2015;122(1):27-37. https://doi.org/10.1111/1471-0528.13032.
  33. Dodd JM, Grivell RM, CM OB, et al. Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy. Cochrane Database Syst Rev. 2017;10:CD012024. https://doi.org/10.1002/14651858.CD012024.pub2.
  34. Jarde A, Lutsiv O, Park CK, et al. Preterm birth prevention in twin pregnancies with progesterone, pessary, or cerclage: a systematic review and meta-analysis. BJOG. 2017;124(8):1163-1173. https://doi.org/10.1111/1471-0528.14513.
  35. Курганский А.В., Иванов Д.О., Савицкий А.Г. Токолитическая терапия в акушерстве: проблемы и решения // Вестник Российской военно-медицинской академии. – 2012. – № 4. – C. 271–275. [Kurganskiy AV, Ivanov DO, Savitskiy AG. Tocolytic therapy in obstetrics: problems and solutions. Vestnik Rossiiskoi voenno-meditsinskoi akademii. 2012;(4):271-275. (In Russ.)]
  36. Derbent A, Simavli S, Gumus II, et al. Nifedipine for the treatment of preterm labor in twin and singleton pregnancies. Arch Gynecol Obstet. 2011;284(4):821-826. https://doi.org/10.1007/s00404-010-1751-3.
  37. Yamasmit W, Chaithongwongwatthana S, Tolosa JE, et al. Prophylactic oral betamimetics for reducing preterm birth in women with a twin pregnancy. Cochrane Database Syst Rev. 2015(12):CD004733. https://doi.org/10.1002/14651858.CD004733.pub4.
  38. Doyle LW, Crowther CA, Middleton P, et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2009(1):CD004661. https://doi.org/10.1002/14651858.CD004661.pub3.
  39. Conde-Agudelo A, Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeksʼ gestation: a systematic review and metaanalysis. Am J Obstet Gynecol. 2009;200(6):595-609. https://doi.org/10.1016/j.ajog.2009.04.005.
  40. Баев О.Р., Васильченко О.Н., Карапетян А.О., Баева М.О. Сравнение токолиза атозибаном и гексопреналином при преждевременных родах до 32 и после 32 недель беременности // Медицинский cовет. – 2017. – № 13. – C. 80–84. [Baev OR, Vasil’chenko ON, Karapetyan AO, Baeva MO. Comparement of localiza atosiban and hexoprenaline in premature delivery before 32 and after 32 weeks of pregnancy. Meditsinskiy Sovet. 2017;(13):80-84. (In Russ.)]
  41. Xu YJ, Ran LM, Zhai SS, et al. Evaluation of the efficacy of atosiban in pregnant women with threatened preterm labor associated with assisted reproductive technology. Eur Rev Med Pharmacol Sci. 2016;20(9):1881-1887.
  42. Flenady V, Reinebrant HE, Liley HG, et al. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Rev. 2014(6):CD004452. https://doi.org/10.1002/14651858.CD004452.pub3.
  43. Arrowsmith S, Neilson J, Wray S. The combination tocolytic effect of magnesium sulfate and an oxytocin receptor antagonist in myometrium from singleton and twin pregnancies. Am J Obstet Gynecol. 2016;215(6):789.e781-789 e789. https://doi.org/10.1016/j.ajog.2016.08.015.
  44. Duckitt K, Thornton S, O‘Donovan OP, Dowswell T. Nitric oxide donors for treating preterm labour. Cochrane Database Syst Rev. 2014(5):CD002860. https://doi.org/10.1002/ 14651858.CD002860.pub2.
  45. Ананьева В.В. Роль биологически активных продуктов плацентарного происхождения в механизмах родовой деятельности: Автореф. дис. … канд. мед. наук. – СПб., 2000. [Anan’eva VV. Rol’ biologicheski aktivnykh produktov platsentarnogo proiskhozhdeniya v mekhanizmakh rodovoy deyatel’nosti. [dissertation]. Saint Petersburg; 2000. (In Russ.)]
  46. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017;3:CD004454. https://doi.org/10.1002/14651858.CD004454.pub3.
  47. Committee on Obstetric P. Committee Opinion No. 713: Antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol. 2017;130(2):e102-e109. https://doi.org/10.1097/AOG.0000000000002237.

Copyright (c) 2019 Kosyakova O.V., Bespalova O.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies